Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 6612.TWO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 6612.TWO and 80,000+ other tickers.
See exactly how 6612.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6612.TWO and 80,000+ other tickers.
ICARES Medicus, Inc. operates as a dedicated nano-medical materials company, engaging in the entire lifecycle from innovation and production to global distribution of advanced ophthalmic medical materials. Its core offerings encompass a range of ocular solutions, most notably intraocular lenses (IOLs) designed to correct visual impairments such as cataracts, nearsightedness (myopia), farsightedness (hyperopia), age-related vision loss (presbyopia), and astigmatism. Additionally, the company supplies sophisticated surgical implantation systems along with comprehensive technical support services. Established in 2011, ICARES Medicus, Inc. maintains its headquarters in Zhubei, Taiwan.
No recent news available.